Randomized trial · people

Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In these phase 2 trials, retatrutide lowered several blood fat markers linked to heart risk with and without diabetes, and inflammation markers fell only in the group without diabetes.

Kind
Randomized trial
Studied in
People
Published
2026
Journal
Diabetes Obes Metab

What they tested

The team wanted to see how retatrutide changes blood fats and inflammation markers tied to heart disease risk in adults with obesity or overweight, with or without type 2 diabetes.

How the study was done

A post hoc look at two randomized, double-blind, placebo-controlled phase 2 trials. Study 1 gave adults with obesity or overweight and type 2 diabetes weekly retatrutide (0.5, 4, 8 or 12 mg), dulaglutide 1.5 mg or placebo (a dummy shot) for 36 weeks, and Study 2 gave adults with obesity but no diabetes weekly retatrutide (1, 4, 8 or 12 mg) or placebo for 48 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Average body mass index was 35.4 kg/m2 in Study 1 and 37.4 kg/m2 in Study 2. Compared with placebo, retatrutide lowered non-HDL cholesterol by up to 21.0% in Study 1 and up to 26.9% in Study 2, and apolipoprotein B (apoB, a count of artery-clogging fat particles) fell by 21.4% and 24.2%. Small LDL particles dropped by 32.6% and 32.3%, and large triglyceride-rich lipoprotein particles by 84.4% and 76.6%. In Study 2 only, high-sensitivity C-reactive protein fell by 54.8% and interleukin-6 by 29.6%, while neither marker changed significantly in Study 1.

What it doesn’t show

This was a post hoc analysis of phase 2 trials, so it was not the main question the trials were built to answer. It measured blood markers, not heart attacks, strokes or other heart events.

The paper

Ruotolo et al. Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes Obes Metab. 2026.

The compound

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo